Renuka Iyer, M.D., will assume the role of CMO at NCCN, focusing on advancing evidence-based cancer care and guideline ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that ...

National Comprehensive Cancer Network overhauls two major resources to help cancer care providers and other stakeholders stay current on cutting edge research into genetic/familial high-risk ...

PLYMOUTH MEETING, PA [October 6, 2025] — Today, the National Comprehensive Cancer Network ® (NCCN ®)—a nonprofit responsible for globally utilized guidelines for cancer care—is sharing new NCCN ...

Tislelizumab's inclusion in the National Comprehensive Cancer Network (NCCN) guidelines for hepatocellular carcinoma (HCC) as a category 1 recommendation marks an advancement in the treatment ...

The new interactive guideline tool represents a major format change for gold-standard NCCN Guidelines. "This is truly the future of cancer treatment guidance," said Crystal S. Denlinger, MD, Chief ...

Invivyd, Inc. has announced that its investigational monoclonal antibody, PEMGARDA® (pemivibart), has been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for ...

The National Comprehensive Cancer Network ® (NCCN ®) - an alliance of leading cancer centers - and the NCCN Foundation ® proudly announce plans to make every book in the library of NCCN Guidelines for ...

William J. Gradishar, MD, provides an overview of the current breast cancer treatment landscape, highlights updates to the NCCN guidelines from 2023 to 2024, and expresses optimism for addressing ...

The National Comprehensive Cancer Network, a coalition of 33 leading U.S. cancer centers, has rolled out a digital navigator for its clinical practice guidelines. The new tool delivers frequently ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) ...

Furthermore, PET scans have a false positive rate, where 50% of positive scans or more are not due to residual lymphoma,” said Mark Roschewski, MD, Senior Clinician and the Clinical Director of the ...